Wall Street Associates’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Wall Street Associates’s Portfolio FLXN Stock Details FLXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.61M	Sell	84,700 -55,800	-40%	-$1.07M	1.06%	18
2016 Q3	$2.75M	Buy	140,500 +27,100	+24%	+$458K	0.94%	33
2016 Q2	$1.7M	Buy	+113,400	New	+$1.43M	0.68%	60
2016 Q1	–	Sell	-142,100	Closed	-$2.74M	–	285
2015 Q4	$2.74M	Sell	142,100 -45,000	-24%	-$781K	0.77%	32
2015 Q3	$2.78M	Hold	187,100	–	–	0.53%	63
2015 Q2	$4.1M	Hold	187,100	–	–	0.39%	90
2015 Q1	$4.21M	Buy	187,100 +37,100	+25%	+$859K	0.4%	91
2014 Q4	$3.03M	Hold	150,000	–	–	0.29%	108
2014 Q3	$2.74M	Hold	150,000	–	–	0.28%	112
2014 Q2	$2.02M	Hold	150,000	–	–	0.17%	166
2014 Q1	$2.47M	Buy	+150,000	New	+$2.59M	0.2%	152

Other funds holding FLXN

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

Wall Street Associates's FLXN Position: Q4 2016 in Review

Wall Street Associates reduced its Flexion Therapeutics, Inc. (FLXN) stake by 40% in Q4 2016, selling an estimated $1.07M and leaving 84,700 shares worth $1.61M. The position accounts for 1.06% of the portfolio, ranked #18.

Wall Street Associates first reported a position in FLXN in Q1 2014 and has held it in 11 quarters since. The position peaked at $4.21M in Q1 2015. 94 funds tracked by Wall St. Rank hold FLXN as of Q4 2016.

Wall Street Associates held 84,700 shares of Flexion Therapeutics, Inc. worth $1.61M as of Q4 2016.
Wall Street Associates sold 55,800 Flexion Therapeutics, Inc. shares in Q4 2016, an estimated $1.07M.
Flexion Therapeutics, Inc. made up 1.06% of Wall Street Associates's portfolio in Q4 2016, its #18 holding.
Wall Street Associates first reported a position in Flexion Therapeutics, Inc. in Q1 2014 and has held it in 11 quarters since.
Wall Street Associates's Flexion Therapeutics, Inc. position peaked at $4.21M in Q1 2015.
94 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q4 2016.

Based on Wall Street Associates's 13F filing for Q4 2016, filed 18 Jan 2017.